NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Stock Looks Undervalued Relative To Fair Value
Eli Lilly stock has delivered a very large 5 year return while valuation checks now give a more mixed read. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside compared with a share price that already embeds high expectations.
Eli Lilly has returned about 362.3% over 5 years, which puts extra focus on whether current holders are paying a premium for that track record.
Expectations around long term demand for its obesity and diabetes treatments can support...